Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunic ( (IMUX) ) has provided an update.
Immunic, Inc. announced on April 1, 2026, that it received formal notice from Nasdaq on March 27, 2026, confirming the company had regained compliance with the exchange’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The compliance was achieved after Immunic’s common stock maintained a closing bid price of at least $1.00 for 20 consecutive business days between February 27 and March 26, 2026.
The resolution of this listing issue removes an immediate risk of delisting and provides greater stability for shareholders and potential investors. It also supports Immunic’s ability to access capital markets as it continues to fund late-stage clinical development of its neurology-focused pipeline.
The most recent analyst rating on (IMUX) stock is a Sell with a $0.95 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, sustained losses, heavy cash burn, and negative equity), which elevates funding and execution risk. Technicals are mixed but not decisively bearish, while corporate events provide some support via substantial financing and leadership additions, partially offset by listing-compliance risk. Valuation signals remain challenged due to negative earnings and no dividend data.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis and has shown activity in earlier-stage studies across multiple sclerosis subtypes and other conditions.
The company is also advancing earlier-stage programs IMU-856 and IMU-381 to build a broader platform targeting neurodegenerative, chronic inflammatory, and autoimmune-related diseases. This positions Immunic in the competitive neurology and immunology biotech space, with an emphasis on neuroprotective and anti-inflammatory mechanisms of action.
Average Trading Volume: 3,524,759
Technical Sentiment Signal: Buy
Current Market Cap: $144.8M
See more insights into IMUX stock on TipRanks’ Stock Analysis page.